BTTC Clinical Trials
Team Studying Three Treatment Regimens
Open BTTC Clinical Trials
The study’s primary objective is to learn if pazopanib when given in combination with topotecan can help to control glioblastoma. The safety of this drug combination will also be studied. A phase II trial of pazopanib and topatecan in adult patients with recurrent glioblastoma.
This study’s primary objective is to determine if prophylactic administration of lacosamide reduces the risk of seizures in patients with a high-grade glioma. Newly diagnosed, post-operative patients are tested during the first year after tumor diagnosis.
This study will evaluate the occurrence of symptoms and their relations to disease progression, as well as the tolerance to treatment regimen. A phase I-II trial everolimus and sorafenib in patients with recurrent high-grade gliomas.
This study will look at evaluating the occurrence of symptoms and their relations to disease progression, as well as the tolerance to the treatment regimen. Phase I/II adaptive randomized trial of bevacizumab versus bevacizumab plus vorinostat in adults with recurrent glioblastoma.
Completed BTTC Clinical Trials
The study evaluated the effects and determined overall survival rates of newly diagnosed malignant glioma patients when administering a combination of bevacizumab (Avastin) and erlotinib (Tarceva) following the completion of radiation therapy with temozolomide (Temodar).
The study determined if temozolomide (Temodar) administered alone or in combination with thalidomide (Thalomid™), isotretinion (Accutane) and/or celecoxib (Celebrex) was effective in the continued treatment of newly diagnosed glioblastoma multiforme patients who already had incurred radiation therapy. Also, the toxicity of this adjuvant treatment was studied.
Participation and Screening Process
The clinical trial, which includes doctors, nurses and other health care professionals, involves an initial review of the patient’s condition or overall health, monitoring the patient during the trial, and maintaining post-trial contact with the patient.
Before performing any of the study’s related procedures, the research team provides the patient with the complete information necessary to make a proper decision about participating in the study. The process is known as the informed consent. It is mandatory that a patient sign an informed consent form (ICF) before the research team performs any procedures.
After the ICF is signed, the patient begins the screening process, which determines participation eligibility. Each study includes a list of inclusion and exclusion criteria and a unique list tailored to the respective treatment being studied.